Image Caption: Epigenetic regulation of receptors. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of ...
WCIA Champaign on MSN
First-of-its-kind lab at U of I aims to treat chronic diseases, develop new cellular therapies
CHAMPAIGN-URBANA, Ill. (WCIA) — A new laboratory at the University of Illinois is one of very few throughout the world to ...
Credit: Getty Images We spoke with endocrinologists to explore the potential of artificial intelligence in the management of chronic disease, including diabetes, obesity, and PCOS. Artificial ...
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee ...
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, ...
Today, 24 April 2025, marks the first-ever World Hormone Day, a global campaign to raise awareness of the vital role of hormones in human health. After three successful years of European Hormone Day, ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.
Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results